Figure 3:

This Figure shows the estimated remaining lifetime risk of a major atherosclerotic cardiovascular events (ASCVD) among 415,274 participants of European ancestry in the UK Biobank. Participants are divided into categories of baseline estimated lifetime risk (5%, 10%, 15%, 20%, and 25%) calculated using the Joint British Societies (JBS3) Lifetime Risk Estimating algorithm (derived from a similar UK population). Within each baseline risk category, participants are then further divided into categories defined by baseline measured Lp(a) concentration. The incremental increase in risk caused by higher Lp(a) concentrations from 30 to 150 mg/dL (75 from 375 nmol/L) was estimated by adding Lp(a) as an independent exposure to the JBS3 risk estimating algorithm. The numbers at the upper end of each bar represent the increment of increased absolute risk above the estimated baseline risk caused by Lp(a). For example, for a person with a baseline risk of 25% and an Lp(a) concentration of 150 mg/dL the absolute risk of a major cardiovascular event increases by 43.1% to 68.1% (versus a person with an Lp(a) of 7 mg/dL). Figure is taken and adapted with permission from the recent EAS Lp(a) Consensus paper and is based on data from the UK Biobank provided by Prof. Brian Ference and Prof. Alberico L. Catapano [1*].